NEUCHATEL, SWITZERLAND--(Marketwired - Oct 10, 2014) - Masimo (NASDAQ: MASI), maker of breakthrough Masimo SET ® Measure-through Motion and Low Perfusion™ Pulse Oximetry, today announced the CE Mark ...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of Eve™, a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97™ Pulse ...
Masimo Corporation MASI received the FDA’s nod for its RD SET sensors to be used with Masimo Measure-through Motion and Low Perfusion SET pulse oximetry. The procedure is aimed at offering improved ...
ZURICH, SWITZERLAND and IRVINE, CA--(Marketwired - Nov 22, 2013) - Masimo (NASDAQ: MASI) announced today that ACUTRONIC Medical Systems AG has integrated Masimo SET ® Measure-through Motion and Low ...
In 2016, Saudi Arabia implemented a mandatory CCHD screening program for all newborns using the Masimo Eve™ Newborn Screening Application on Radical-7 ® Pulse CO-Oximeters ® with SET ® Measure-through ...
Masimo today announced the results of a prospective study published in the International Journal of Neonatal Screening in which researchers in Marrakesh, Morocco, conducted the first Moroccan study on ...
Smaller, Flexible Sensors Are More Comfortable for Patients, Easier to Apply for Clinicians "Masimo's new low-profile sensors are not only flatter and easier to apply, but the added pliability allows ...
About a year after beginning its full market launch, Masimo’s W1 smartwatch can now be used as a medical device in the U.S. The wearable device has earned FDA clearance for its medical applications, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results